Rhythm Pharmaceuticals Inc
RYTM101.390USD
+1.180+1.18%
交易中 （美东）报价延迟15分钟
6.48B总市值
亏损市盈率 TTM
关于 Rhythm Pharmaceuticals Inc 公司
Rhythm Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司专注于推进其黑皮质素-4 受体 (MC4R) 激动剂，包括其主要资产 IMCIVREE，这是一种精准医疗，旨在治疗由罕见的 MC4R 通路疾病引起的暴食症和严重肥胖症。IMCIVREE 已获得美国食品药品管理局 (FDA) 批准，用于治疗因阿片黑皮质素原 (POMC)、前蛋白转化酶枯草溶菌素/kexin 1 型 (PCSK1) 或瘦素受体 (LEPR) 缺乏而导致的单基因或综合征性肥胖的成人和 6 岁及以上的儿童患者的慢性体重管理，经 FDA 批准的测试确定，POMC、PCSK1 或 LEPR 基因中的变异被解释为致病、可能致病或意义不明 (VUS)；或 Bardet-Biedl 综合征 (BBS)。该公司正在 II 期和 III 期试验中评估 setmelanotide 对治疗因与 MC4R 通路相关的众多基因之一变异而导致的肥胖症的效果。
Rhythm Pharmaceuticals Inc简介
公司代码RYTM
公司名称Rhythm Pharmaceuticals Inc
上市日期Oct 05, 2017
CEO- -
员工数量283
证券类型Ordinary Share
年结日Oct 05
公司地址222 Berkeley Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02116
电话18572644280
网址https://rhythmtx.com/
公司代码RYTM
上市日期Oct 05, 2017
CEO- -
Rhythm Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
7.00K
+133.33%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Independent Director
Independent Director
7.00K
+133.33%
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Alastair (Al) Garfield, Ph.D.
Dr. Alastair (Al) Garfield, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
暂无数据
地区USD
名称
营收
占比
United States
96.11M
73.86%
International
34.02M
26.14%
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
8.44%
RA Capital Management, LP
8.37%
PRIMECAP Management Company
7.34%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
5.39%
其他
64.58%
持股股东
持股股东
占比
Baker Bros. Advisors LP
8.44%
RA Capital Management, LP
8.37%
PRIMECAP Management Company
7.34%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
5.39%
其他
64.58%
股东类型
持股股东
占比
Investment Advisor
34.99%
Investment Advisor/Hedge Fund
28.82%
Hedge Fund
14.76%
Venture Capital
13.98%
Private Equity
4.02%
Research Firm
3.76%
Bank and Trust
0.73%
Individual Investor
0.67%
Pension Fund
0.35%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
449
67.58M
101.74%
-2.34M
2025Q2
451
66.54M
100.20%
-6.36M
2025Q1
464
66.24M
104.13%
-6.91M
2024Q4
438
66.17M
104.69%
-7.75M
2024Q3
414
68.98M
112.28%
-7.86M
2024Q2
402
70.62M
115.59%
-5.66M
2024Q1
385
68.75M
112.78%
-8.84M
2023Q4
369
67.33M
113.30%
-8.52M
2023Q3
350
68.72M
116.31%
-2.96M
2023Q2
327
67.69M
118.97%
+564.21K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
5.60M
8.44%
--
--
Jun 30, 2025
RA Capital Management, LP
5.56M
8.37%
-523.05K
-8.60%
Jun 30, 2025
PRIMECAP Management Company
4.88M
7.34%
-909.28K
-15.71%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.91M
5.88%
-93.66K
-2.34%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
5.39%
+144.19K
+4.20%
Jun 30, 2025
New Enterprise Associates (NEA)
2.91M
4.38%
--
--
Jun 30, 2025
Perceptive Advisors LLC
2.42M
3.64%
-130.15K
-5.11%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.91M
2.87%
+272.55K
+16.66%
Jun 30, 2025
State Street Global Advisors (US)
1.91M
2.87%
-63.13K
-3.20%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.63M
2.45%
+288.38K
+21.50%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
ALPS Medical Breakthroughs ETF
3.84%
Innovator IBD 50 Fund ETF
2.96%
Virtus LifeSci Biotech Products ETF
2.73%
Invesco Dorsey Wright Healthcare Momentum ETF
2.71%
Harbor Health Care ETF
2.15%
Harbor Human Capital Factor US Small Cap ETF
2.03%
iShares Health Innovation Active ETF
1.85%
SPDR S&P Biotech ETF
1.29%
Federated Hermes MDT Small Cap Core ETF
0.78%
Direxion Daily S&P Biotech Bull 3X Shares
0.78%
查看更多
ALPS Medical Breakthroughs ETF
占比3.84%
Innovator IBD 50 Fund ETF
占比2.96%
Virtus LifeSci Biotech Products ETF
占比2.73%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.71%
Harbor Health Care ETF
占比2.15%
Harbor Human Capital Factor US Small Cap ETF
占比2.03%
iShares Health Innovation Active ETF
占比1.85%
SPDR S&P Biotech ETF
占比1.29%
Federated Hermes MDT Small Cap Core ETF
占比0.78%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.78%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
